ESCRS - Supplement: New Medical Therapies and Modern MIGs Address Unmet Needs in Galucoma and Cataract Patient Care ;
ESCRS - Supplement: New Medical Therapies and Modern MIGs Address Unmet Needs in Galucoma and Cataract Patient Care ;
Supplements

Supplement: New Medical Therapies and Modern MIGs Address Unmet Needs in Galucoma and Cataract Patient Care

Supplement: New Medical Therapies and Modern MIGs Address Unmet Needs in Galucoma and Cataract Patient Care

According to the 2020 ESCRS Clinical Trends Survey, an average of 21% of patients prescribed one or two topical glaucoma medications and 27% of those prescribed more than two topical glaucoma medications to control their condition are not compliant (Figure 1). It is a significant number of patients.

Tags: glaucoma
Latest Articles
Glaucoma Treatment Under Pressure

New techniques and technologies add to surgeons’ difficult decisions

Read more...

Outside the Box, Inside the Pipeline

Researchers are tackling glaucoma diagnosis and treatment from all sides.

Read more...

The EHDS Is Ready for the Green Light

If proposal is approved, Europe could see better access to, and exchange and use of, health data.

Read more...

ESCRS to Release Guidelines for Cataract and Refractive Surgery

Comprehensive approach to the safest and most effective modern surgery.

Read more...

Barry Fellowship Opens Up ‘Whole New Field of Thought’

The 2022 recipient combines theoretical and practical to learn new treatments.

Read more...

Digitalising the OR—Experience and Perspectives

Benefits include saving time and improving outcomes.

Read more...

ESCRS Heritage Programme

Visionaries past and present.

Read more...

Dynamic Measures Needed for Quality of Vision

Functional visual acuity testing and straylight metering may better reflect real-world conditions.

Read more...

What Is Stopping Digital OR Adoption?

Ophthalmologists know the benefits—now it’s time to construct the right plan.

Read more...

Time to Move Beyond Monofocal IOLs?

European surgeons appear hesitant to first offer other presbyopia-correcting options to patients.

Read more...

;